Neutralizing Antibody Given after Paralysis Onset Reduces the Severity of Paralysis Compared to Nonspecific Antibody-Treated Controls in a Mouse Model of EV-D68-Associated Acute Flaccid Myelitis.

Author: ClarkePenny, FrostJoshua, RudyMichael J, TylerKenneth L

Overview

This study investigated the potential of virus-specific immunotherapy for treating acute flaccid myelitis (AFM) caused by enterovirus D68 (EV-D68) infection. Treatment with a human-mouse chimeric monoclonal antibody after the onset of paralysis in mice slowed the progression of weakness and reduced viral titer. The study highlights the need for early treatment of AFM if recent EV-D68 infection is suspected.

Paper Details　

Original Abstract of the Article :

Enterovirus D68 (EV-D68) can cause mild to severe respiratory illness and is associated with a poliomyelitis-like paralytic syndrome called acute flaccid myelitis (AFM). Most cases of EV-D68-associated AFM occur in young children who are brought to the clinic after the onset of neurologic symptoms. ...See full text at original site

Dr.Camel's Paper Summary Blog

EV-D68-Associated AFM: A Race Against Time

Enterovirus D68 (EV-D68) is a virus that can cause a wide range of symptoms, from mild respiratory illness to a serious neurological condition called acute flaccid myelitis (AFM). This study explores the potential of neutralizing antibodies as a treatment for AFM, focusing on their effectiveness when administered after the onset of paralysis.

The researchers developed a mouse model of EV-D68-associated AFM and investigated the effect of administering an EV-D68-specific antibody after the onset of paralysis. They found that treatment with the antibody significantly improved paralysis outcomes, demonstrating its potential to mitigate the severity of AFM.

Neutralizing Antibodies: A Potential Weapon Against AFM

This study offers promising evidence for the use of virus-specific immunotherapy in the treatment of EV-D68-associated AFM. It emphasizes the importance of early intervention, as treatment initiated after the onset of paralysis can still have a positive impact. The researchers advocate for prompt diagnosis and treatment of AFM, especially in individuals with suspected EV-D68 infection.

Dr.Camel's Conclusion

This study, like a swift desert wind, carries a message of hope for those affected by EV-D68-associated AFM. It suggests that neutralizing antibodies can offer a potential avenue for treatment and underscores the urgency of early intervention in managing this challenging neurological condition.